From todays AFR, page-5

Hi fourdollars

I do not profess to be an informed medico that understands all the technical aspects of the many medical companies that report to shareholers on ASX.

I have held SRX for a very long time and always taken advantage of small sell offs, I did in fact purchase more stock on 17 March and still hold them, a pretty uniformed decision?

But my observation is with companies reporting clinical trials the most important aspect of the report is did it reach it's PRIMARY end point, that is reality, it was not until the ASCO abstract paper in May that any sense was being made of the findings.

Meanwhile the share price had been hammered and a great many people lost a lot of money and it created enormous confusion, looking at the HC comments at this time, there was not one person who understood what had happened leading up to ASCO paper.

I was sitting in a motel room in Canberra in June listening to the presentation about the ASCO paper and there still seemed to be a number of unanswered questions even then.

Like you I am not interested in sugar coated announcements, just factual information, but it needs to include all the facts, in what are extremely technical trials.

I hope we do not have to go through what transpired last year when the next set of data is released late this year.

Just my thoughts. Guess we will have to agree to disagree on Gilman.